Koers Allarity Therapeutics, Inc. Nasdaq Stockholm
Aandelen
ALLR
US0167441049
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 197K 2,12 mln. 182K |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -16 mln. -171 mln. -14,72 mln. | Nettowinst (verlies) 2025 * | -28 mln. -300 mln. -25,77 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,25
x | K/w-verhouding 2025 * |
-0,41
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 13,55% |
Recentste transcriptie over Allarity Therapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Jensen
FOU | Founder | 46 | 01-06-20 |
Joan Brown
DFI | Director of Finance/CFO | 71 | 21-09-21 |
Chief Tech/Sci/R&D Officer | 63 | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 56 | 01-10-22 | |
Thomas Jensen
FOU | Founder | 46 | 01-06-20 |
Joseph Vazzano
BRD | Director/Board Member | 40 | 01-08-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,42% | 115 mld. | |
+11,84% | 106 mld. | |
-1,05% | 21,96 mld. | |
-14,15% | 21,84 mld. | |
-5,29% | 19,21 mld. | |
-4,16% | 18,08 mld. | |
-38,29% | 17,71 mld. | |
+7,99% | 14,32 mld. | |
+36,24% | 12,42 mld. |